Chattanooga Oncology & Hematology Associates (COHA) has signed a Letter of Intent to merge with Nashville-based Tennessee Oncology. The merger will be finalized during the next few weeks, and will create one of the largest networks of physician-owned oncology practices in the nation.
Effective Jan. 1, 2013, COHA will change its name to Tennessee Oncology. COHA patients will have expanded access to new services and clinical trial research provided by the same physicians and staff in the same four locations that have been serving cancer patients in Chattanooga and surrounding areas since 1986.
“We are excited about this merger and what it means for the future of our practice,” said Edward Arrowsmith, M.D, president of COHA. “It is the best way for us to navigate the changing healthcare environment and remain an independent community oncology practice. Most importantly, it allows us to continue providing the best possible care and offer the most innovative cancer treatments and services.”
Tennessee Oncology has a longstanding research alliance with COHA through a strategic partnership with the Sarah Cannon Research Institute, and will now offer expanded access to clinical trials and specialized services to all COHA patients. This includes access to Tennessee Oncology’s Park Pharmacy, a full-service pharmacy dedicated to oncology and hematology medications not commonly stocked in community retail pharmacies.
“COHA initiated discussions with us several months ago, and we believe this merger is a win-win for both parties as our two practices share very similar philosophies, especially when it comes to making sure patients always come first,” said Tennessee Oncology CEO Jeff Patton, M.D. “We are both committed to advancing the science of oncology through clinical trial participation and to making sure patients have access to the same clinical trials available through academic institutions in their own communities close to their homes.”